GlassScriptPhysician profile
Heather Cypher
NPI 1033835772
$7,178.05
in general payments reported to CMS, 2019-2025
20 companies · $2,765 in 2025
The $2,765 reported for 2025 was more than what 96% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $48.44 · 2023: $2,974 · 2024: $1,391 · 2025: $2,765.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,115 · Education: $14.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,114.96 |
| Education | $14.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axsome Therapeutics, INC. | $1,449.45 | 2023-2025 | Auvelity, Sunosi |
| Abbvie INC. | $1,359.88 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $723.46 | 2023-2025 | Austedo Xr, Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $658.81 | 2023-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $445.22 | 2022-2025 | Rexulti, Nuedexta |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $371.04 | 2022-2025 | Caplyta |
| Supernus Pharmaceuticals, INC. | $358.27 | 2023-2025 | Qelbree, Qelbree |
| Alkermes, INC. | $342.47 | 2023-2025 | Aristada, Lybalvi, Vivitrol |
| Lundbeck LLC | $330.46 | 2023-2025 | Rexulti, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $302.73 | 2024-2025 | Fanapt, Hetlioz, Ponvory |
| Neurocrine Biosciences, INC. | $261.68 | 2023-2025 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $178.39 | 2023 | Quviviq |
| Almatica Pharma LLC | $135.21 | 2023-2025 | Gralise, Loreev Xr |
| Corium, LLC | $83.95 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $50.46 | 2025 | Jornay Pm |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $45.80 | 2023-2025 | Trintellix |
| Lilly USA, LLC | $33.59 | 2025 | Zepbound |
| Novo Nordisk INC | $19.47 | 2025 | Wegovy |
| Tris Pharma INC | $13.94 | 2024 | Dyanavel Xr |
| Sage Therapeutics, LLC | $13.77 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Cypher listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.